Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody to treat advanced (metastatic) non-small cell lung cancer.
別名(Alternative names)
BMS-936558,MDX-1106,ONO-4538
靶點;物種(Specificity target name;species)
PDCD1/PD1/CD279[Homo sapiens]
活性研究(體外/體內(nèi)研究)(Activity in vitro)
Nivolumab binds to CHO cells expressing PD-1 with an EC50 of 1.66 nM, but does not bind to the parental CHO cell line. Nivolumab binds to PD-1 on activated T cells with an EC50 of 0.64 nM. Nivolumab also inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with IC50 values of 2.52 and 2.59 nM, respectively. Nivolumab (1.5 ng/mL) can enhance T-cell reactivity in the presence of a T-cell receptor stimulus.
種類(Species)
Homo sapiens
受體鑒定(Receptor identification)
IgG4-kappa
分子量(MV)
143599.09 Da
CAS
946414-94-4
存儲條件(Storage)
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.